Trastuzumab deruxtecan (solution)
CAT:
804-HY-138298-01
Size:
1 mg
Price:
Ask
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: Yes
Trastuzumab deruxtecan (solution)
- CAS Number: 1826843-81-5
- UNSPSC Description: Trastuzumab deruxtecan (T-DXd; DS-8201a) (solution) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer[1][2].
- Target Antigen: Antibody-Drug Conjugates (ADCs); EGFR
- Type: ADC Related
- Related Pathways: Antibody-drug Conjugate/ADC Related;JAK/STAT Signaling;Protein Tyrosine Kinase/RTK
- Field of Research: Cancer
- Assay Protocol: https://www.medchemexpress.com/trastuzumab-deruxtecan-solution.html
- Smiles: [Trastuzumab deruxtecan]
- Molecular Weight: 153000 (average)
- References & Citations: [1]Kotani D, et, al. Trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer. Ther Adv Med Oncol. 2021 Jan 7;13:1758835920986518.|[2]Ogitani Y, et, al. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016 Jul;107(7):1039-46.|[3]Iwata TN, et, al. [Fam-] trastuzumab deruxtecan (DS-8201a)-induced antitumor immunity is facilitated by the anti-CTLA-4 antibody in a mouse model. PLoS One. 2019 Oct 1;14(10):e0222280.|[4]Kumagai K, et al. Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2-targeting Ab-drug conjugate, in monkeys. Cancer Sci. 2020 Dec;111(12):4636-4645.
- Shipping Conditions: Dry Ice